Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $42
Buy Rating for Anavex Life Sciences Due to Solid Financials and European Market Potential
Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital
Anavex Life Sciences Is Maintained at Buy by D. Boral Capital
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $42
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $42
Promising Long-Term Benefits and Market Potential of Blarcamesine in Alzheimer's Treatment Justify Buy Rating for Anavex Life Sciences
Anavex Life Sciences Analyst Ratings
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Raises Target Price to $42
Anavex Life Sciences: Buy Rating Driven by European Approval Prospects and Strong Financial Position
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
Anavex Life Sciences Analyst Ratings
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Anavex Life Sciences Is Maintained at Buy by D. Boral Capital
Anavex Life Sciences Price Target Maintained With a $46.00/Share by D. Boral Capital
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
Anavex Life Sciences Analyst Ratings